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Although positive inotropic drugs produce short-term hemo-
dynamic benefits in chronic heart failure, there is a persist-
ent, unresolved concern that prolonged pharmacologic stim-
ulation of the failing heart adversely affects the long-term
survival of these severely ill patients . This issue was first
raised during the early experience with these drugs, became
an important focus of controversy as research with these
agents continued and gained widespread attention after the
completion of large scale, placebo-controlled trials . Al-
though nearly all positive inotropic agents have been impli-
cated as having potentially adverse effects on mortality .
there is particular concern about drugs (beta-adrenergic
agonists and phosphodiesterase inhibitors) that enhance
cardiac contractility by increasing intracellular cyclic aden-
osine monophosphate (AMP). Two mechanisms have been
proposed (I) to explain a detrimental effect of positive
inotropic agents on survival: accelerated disease progression
and exacerbation of ventricular arrhythmias .
Accelerated Progression of the Underlying
Heart Disease
Congestive heart failure is a progressive disorder, but
there are persistent concerns that positive inotropic drugs
may accelerate the rate of disease progression and thereby
may adversely affect the survival of these patients .
Biochemical basis for accelerated disease prgression . The
depression of cardiac contractility seen in patients With
chronic heart failure is not only related to a loss of function-
ing myocardium, but is also the result of a decline in the
inotropic state of viable myocardial tissue . The rate of
delivery of calcium to myofibrillar elements is reduced in
chronic heart failure (2), and thus the activation of cardiac
contractile proteins is impaired
. Is this defect beneficial or
detrimental? Katz (3) has postulated that the depression of
contractility is an important compensatory mechanism that
decreases energy utilization by the dilated heart and thereby
prolongs the long-term survival of the cardiac muscle cell .
Consequently, any drug-induced augmentation of the inotro-
pic state could produce temporary hemodynamic improve-
ment at the expense of increasing energy consumption and
accelerating cell death. Such a mechanism may be particu-
lady important in patients with coronary artery disease, in
whom the balance between energy production and energy
consumption is especially precarious . In these patients,
positive inotropic agents may increase myocardial oxygen
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consumption, enhance the myocardial production of lactate
and exacerbate myocardial ischemia (4,5) .
This abnormality in myocardial calcium transport and
contractility may be related to a defect in
cyclic AMP
generation in the failing heart. The myocardium in experi-
mental and clinical heart failure shows a reduced sensitivity
to pharmacologic interventions that act by increasing cyclic
AMP (beta-receptor agonists, glucagon and phosphodiester-
ase inhibitors) but responds normally to drugs that increase
contractility by other mechanisms (digitalis and calcium) (6-
9) . This selective reduction in inotropic responsiveness may
represent an attempt by the failing heart to minimize the
potential adverse effects of intracellular cyclic AMP-a
nucleotide that appears to be toxic to myocardial cells . Such
toxicity is enhanced by agents that act to increase intracel-
lular cyclic AMP, either by promoting its synthesis (beta-
receptor agonists) or by retarding its degradation (phospho-
diesterase inhibitors) (10-12) .
Clinical evidence far accelerated disease prgrrsslen . Early
uncontrolled hemodynamic studies (4,13,14) noted that left
ventricular dysfunction progresses during long-term treat-
ment with positive isotropic drugs, but it remained uncertain
whether such progression reflected the natural history of the
disease or was the consequence of long-term inotropic
therapy
. These observations raised important concerns,
however, when it became apparent that hemodynamic pro-
gression did not occur during long-term treatment with
placebo or vasodilator drugs (4,15,16) . Similarly, exercise
tolerance generally remains stable or improves (because of a
training effect) during long-term placebo therapy in patients
with chronic heart failure (15,16) . In contrast, exercise
tolerance may deteriorate during the course of treatment
with the phosphodiesterase inhibitor milrinone, perhaps as a
consequence of accelerated disease progression (17) .
These concerns about accelerated disease progression
have recently been heightened by the results of a large scale,
double-blind, placebo-controlled randomized study (18) of
oral milrinone in moderate to severe chronic heart failure . In
this multicenter trial, 155 patients treated with digitalis and
diuretics underwent invasive hemodynamic testing before
and after 12 weeks of therapy with either milrinone or
placebo ; in a third group of patients, milrinone was substi-
tuted for digitalis . Hemodynamic measurements were car-
ried out before the first and last scheduled doses of milrinone
to determine if a shift in the baseline (premilrinone) hemo-
dynamic state had occurred during the 12 week treatment
period that might indicate accelerated disease progression .
In patients treated with milrinone, values for cardiac index
and stroke volume index were lower, and values for left
ventricular filling pressure and systemic vascular resistance
were higher, after 3 months of treatment with the drug than
on entry into the study. A similar deterioration in cardiac
performance was not seen in patients in this study treated
with placebo . Although some investigators have suggested
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that these hemodynamic changes reflect the occurrence of
rebound vasoconstriction rather than disease progression,
rebound hemodynamic events have not been reported after
the withdrawal of long-term milrinone therapy (19)
.
The
controlled data from this multicenter trial 1181 enhance
concerns that long-term treatment with positive inotropic
agents accelerates the rate of progression of left ventricular
dysfunction in patients with chronic heart failure .
Exacerbation of Ventricular Tachyarrhyrhntias
Positive inotropic drugs may also adversely affect the
mortality of patients w,th chronic heart failure by increasing
the frequency and complexity of ventricular tachyarrhyth-
mias and thereby enhancing the probability of sudden death,
Biochemical bans for proarrhythmia. Although an in-
crease in cytosolic calcium is important in maintaining
contractile function during excitation-contraction coupling,
such an increase also leads to the development of delayed
afterdepolarizations, which may play a role in the pathogen-
esis of arrhythmias (20) . Nearly all currently available ino-
tropic agents enhance the amount of activator calcium
released into the cytosol during systole and thus can produce
such delayed afterdepolarizatidns . Moreover, the raised
levels of cyclic AMP seen during treatment with oral beta-
receptor agonists and phosphodiesteras, inhibitors may en-
hance automaticity and triggered responses, further increas-
ing the potential for proarrhythmia
(21) .
Ventricular
arrhythmias may also be provoked if positive inotropic
agents act to exacerbate myocardial iychemia .
Clinical evidence for proarrhythmia
. In early uncon-
trolled studies, complex ventricular arrhythmias were fre-
quently noted after treatment with positive inotropic drugs,
but these reports were difficult to interpret because serious
arrhythmias are common in patients with chronic heart
failure in the absence of inotropic therapy. Additional con-
cerns were raised, however, when ventricular arrhythmias
were found to be consistently exacerbated during treatment
with beta-receptor agonists and phosphodiesterase inhibi-
tors
. Every study that performed intensive electrocardio-
graphic (ECG) monitoring (22,23) before and after short- and
long-term treatment with these drugs noted an increase in
the frequency or the complexity of ventricular arrhythmias .
Some of these arrhythmias became symptomatic for the first
time after treatment with positive inotropic drugs
(4) .
This risk of proarrhythmia during long-term treatment
with positive inotropic drags has now been confirmed in
controlled clinical trials . In a recently completed random-
ized study (24), 103 patients with heart failure underwent
ambulatory ECG monitoring before and after 3 months of
treatment with either milrinone or placebo
. Worsening
arrhythmias were noted more frequently in patients treated
with milrinone than in those not treated with the drug (I8
PACKER
	
563
PROTAGONIST'S VIEWPOINT
versus 4%Gi . This result was particularly striking in view of
the fact that patients with clinically important arrhythndas
related to mitrinone withdrew from the trial before the end of
the study and were excluded from the analysis . The inci-
dence of proarrhythmia with milrinone was particularly
marked in patients not receiviag antiarrhythmic drugs (8 of
29 patients receiving milrinone versus I of 31 patients not
receiving milrinone) (24) . In a large mutticenter placebo-
controlled trial (P-706) (24 .25), the frequency of ventricular
arrhythmias reported as adverse reactions was higher in
milrinone-treated patients than in patients not treated with
the drug (15 [12 .6%) of 119 patients receiving mitrinone
versus 5 [4.5%] of Ill patients not receiving milrinone) ;
milrinone therapy was also associated with a higher fre-
quency of supraventricular arrhythmias. Most importantly,
when. the results of double-blind controlled trials were com-
bined, nine arrhythmic events occurred during treatment
with milrinone that were classified by the investigator as
llfe-thremening (primarily symptomatic ventricular tachy-
cardia and ventricular fibrillation) ; in contrast, only one such
event was reported in patients randomly assigned to the
control groups (24) . Most of these events occurred early
during the course of therapy and required the withdrawal of
milrinone or the addition of antiarrhythmic drugs .
Reduced Long-Term Survival
The evidence (cited in the preceding paragraphs) derived
from both historical-controlled and placebo-controPed trials
indicates that long-term treatment with positive inotropic
agents is associated with enhanced ventricular arrhythmias
and accelerated disease progression . Are these deleterious
effects accompanied by an increase in the mortality of
patients with chronic heart failure?
Experience with intravenous and oral catecbol mines. The
results of controlled and uncontrolled clinical trials suggest
that long-term therapy with beta-adrenergic agonists ad-
versely affects the survival of patients with chronic heart
failure. Dawson et al. (26) reported a disturbing 32% 3 month
mortality rate in 63 patients with mild to moderate heart
failure treated with the oral beta-receptor agonist, pirbute-
rol ; this event rate was higher than expected in this patient
cohort . Fears about enhanced mortality were raised further
by the results of a double-blind controlled trial of intermit-
tent intravenous dobutamine. In that study
(27),
60 patients
with severe heart failure were randomly assigned to treat-
ment with either dobutamine or placebo . Both agents were
administered intravenously through au indwelling catheter
for 48 h/week for 24 weeks . The original study design called
for the enrollment of 100 to 200 patients, but the trial was
stopped prematurely by the manufacturer (after only 60
patients had entered the study and only 25 patients had
completed 8 weeks of treatment), when it was noted that IS
of The 20 deaths occurred in patients who were assigned or
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had crossed over to treatment with dobutamine . These
findings are particularly noteworthy in view of the poor
prognosis associated with high circulating levels of catechol-
amines when these are observed to occur spontaneously in
chronic heart failure (28) .
This unfavorable experience
with
beta-receptor agonis ts
contrasts markedly with reports that beta-adrenergic antag-
onists may exert a beneficial e f ect on the survival ofpatients
with chronic
heart failure .
In patients recovering from an
acute myocardial infarction, beta-blocker therapy reduces
cardiovascular mortality and sudden death ; this prolongation
of survival is most apparent in patients with heart failure or
with a history of chronic heart failure at the time of random-
ization (29,30). These benefits can no longer be discerned
when beta-blockers with intrinsic sympathomimetic activity
are evaluated in the postinfarction period . Beta-bleckers
without intrinsic sympathomimetic activity decrease the
mortality by 30%, whereas mortality does not appear to he
favorably affected by beta-blocking agents with intrinsic
sympathomimetic activity (30) . If therapy with a beta-
blacker with intrinsic sympathomimetic activity is initiated
> I year after an index infarction, mortality may be increased
by treatment (31). These data suggest that positive inotropic
drugs that stimulate the sympathetic nervous system may
exert a deleterious effect on the survival of patients with
heart failure .
Experience with phosphodiesterase inhibitors, Early expe-
rience in uncontrolled studies with amrinone, milrinone and
enoximone indicated that the mortality of patients with
chronic heart failure treated with these drugs was very
high-a pooled I year mortality rate of 74% notably higher
than the 45% I year pooled mortality rate noted in trials of
patients treated with vasodilator drugs (t) . Such observa-
tions were difficult to interpret, however, because this dif-
ference in survival could have been related to differences in
the baseline characteristics of the patients in the two treat-
ment groups . Some investigators suggested that patients
treated with positive inotropic drugs had more advanced
heart disease than those who received vasodilators, yet this
hypothesis could not be confirmed on formal examination . In
fact, treatment with phosphodiesterase inhibitors was found
to contribute independently to the prediction of high mortal-
ity in these patients (32).
Controlled trials with phosphodiesterase inhibitors have
failed to allay concerns that treatment with these drugs may
adversely affect the survival of patients with chronic heart
failure . In the largest placebo-controlled trial of a positive
inotropic agent carried out to date (25), the 3 month mortal-
ity was higher in milrinone-treated patients than in those not
receiving the drug (15 of 119 versus 6 of Ill patients) (p =
0.06) . When all available controlled studies of milrinone in
heart failure were combined (24), the 3 month mortality rate
was9.2% in patients treated with milrinone, but only 5 .8% in
patients not treated with the drug (p = 0 .12) . When these
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controlled data were presented by the manufacturer of
milrinone (Sterling Drug, Inc .) to the Food and Drug Admin-
istration, the sponsor suggested that the higher mortality
with milrinone could be explained by an unequal randamiza-
tion of patients with low values for ejection fraction to the
milrinone-treated group . Adjustment of these mortality rates
for differences in ejection fraction narrowed the differences
noted between the groups, but
;a all analyses, the mortality
rate of patients treated with milrinone was higher than that of
patients not receiving milrinone. This was true even when
the analysis was restricted to patients at high risk of death
(that is, those with a left ventricular ejection fraction <20%) ;
in this subgroup, 21% of milrinone-treated patients-but
only 12% of patients not treated with milrinone-died during
the 3 month observation period (24) . Although these differ-
ences did not reach statistical significance, none of these
trials enrolled enough patients or followed up patients for
sufficiently long periods to adequately evaluate the impact of
milrinone on survival . The calculation of odds ratios (to
express potential risk) suggested that the magnitude of the
excess mortality seen in patients treated with milrinone
could he as large as 200 to 600%
. The Cardio-Renal Advisory
Committee of the Food and Drug Administration concluded
that concerns that milrinone may exert an adverse effect on
survival could not be resolved by the data presented by the
manufacturer (24). At least one other pharmaceutical com-
pany (Warner-Lambert) has stopped its development pro-
gram of positive inotropic agents on the basis of concerns
about an increase in mortality with its own phosphodiester-
ase inhibitor (CI-914) .
This experience with phosphodiesterase inhibitors stands
in striking contrast to the favorable ef ects on survival
reported in studies ofpatients with heart failure treated with
vasodilator drugs (33,34). Therapy with both direct-acting
vasodilators and converting enzyme inhibitors prolongs life ;
this beneficial effect has (in part) been attributed to the
reduction in loading conditions in the failing heart that can be
expected to follow the action of these drugs on the peripheral
circulation. Insofar as most phosphodiesterase inhibitors are
potent vasodilator drugs that produce sustained decreases in
ventricular filling pressures and systemic vascular resistance
during long-term treatment, we might expect these drugs to
favorably influence mortality as well. The observation of an
adverse (rather than a favorable) trend in controlled studies
with milrinone suggests that the inotropic action of these
agents is associated with a deleterious effect on long-term
survival .
Conclusions . Despite biochemical studies that suggest
that cyclic AMP may be toxic to myocardial cells, physicians
have utilized drugs that increase cyclic AMP in an effort to
support the failing heart . Short-term therapy with beta-
receptor agonists and phosphodiesterase inhibitors produces
marked hemodynamic benefits, but long-term treatment with
these drugs appears to be accompanied by accelerated
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disease progression, worsening ventricular lachyarrhyth-
mias and an adverse effect on survival . Such deleterious
effects have now been observed in both historical- and
placebo-controlled studies. These risks of positive isotropic
therapy would be acceptable, however . if the benefits of
treatmentt were great-particularly when symptoms become
refractory to maximal conventional therapy . Additional tri-
als are needed to explore this possibility .
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In the last several years a number of new nonglycoside
positive inotropic agents have been developed for the treat-
ment of patients with congestive heart failure
. These new
drugs fall into two major categories: the beta-adrenergic
agonists and the phosphodiesterase inhibitors (1) . Both
classes of agents produce marked hemodynamic improve-
ment and appear in clinical practice to exert a substantially
greater positive inotropic action than does digitalis
. The
intravenously administered beta-adrenergic agonists, dopa-
mine and dobutamine, are now widely used in the short-term
management of patients with heart failure. In 1978, the initial
hemodynamic effects of intravenous amrinone were reported
and, subsequently, this agent was approved by the Food and
Drug Administration for the short-term management of
severe heart failure
. Several new second-generation phos-
phodiesterase inhibitors (such as milrinone, enoximone and
piroximone) are available orally on an investigational basis .
Theoretical concerns. The development of potent positive
inotropic agents has led to concerns that sustained inotropic
stimulation may produce an adverse effect on the survival of
patients with congestive heart failure . This concern, initially
articulated by Katz (2,3) and subsequently by Packer et al .
(4,5), was based on three theoretical fears . First, positive
inotropic agents would adversely affect myocardial energet-
ics, thereby hastening the rate of myocardial deterioration .
Second, agents that increase myocardial cyclic adenosine
monophosphate (AMP) or calcium would provoke complex
ventricular arrhythmias, thereby leading to an increase in the
incidence of sudden cardiac death
. Third, agents that in-
crease myocardial calcium would impair myocardial-dias-
tolic relaxation, thereby leading to an increase in diastolic
wall stress and cardiac filling pressures .
It is important that these theoretical issues be addressed
by prospective, placebo-controlled, double-blind trials . It is
particularly imperative that we avoid conclusions based on
uncontrolled observations. Although the results of uncon-
trolled studies may appear to support certain theoretical
arguments, other explanations for observed phenomena are
usually possible and cannot be excluded in the absence of
SACC Val. IL No. 2
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controlled data . This important point was emphasized by
Packer and Leier (5), who noted, "Most of the patients
treated with phosphodiesterase inhibitors were severely ill,
were deteriorating clinically before therapy and had previ-
ously failed vasodilator therapy, often including captopril ."
These authors concluded that "it is possible that unmea-
sured variables were present before therapy in patients
treated with positive inotropic agents that contributed im-
portantly both to the decision to refer such patients for
therapy and to their extremely poor long-term prognosis
."
Controlled trials are now available, which provide informa-
tion regarding the effects of long-term positive agents on the
clinical status, functional capacity and survival of patients
with chronic heart failure .
Effect of beta-adrenergic agonists on survival in heart
failure
. Attempts to use orally active beta-adrenergic all
ists for the treatment of heart failure have not been success-
ful, in large part because tolerance develops to the hemody-
namic effects of such agents during long-term therapy
(1).
Accordingly, patients fail to show persistent hemodynamic
and clinical responses to pirbnterol and prenalterol after
these orally active betaadrenergic agonists have been ad-
ministered for several days (6,7)
. This hemodynamic atten-
uation appears to be related to a down-regulation of beta-
adrenergic receptors (7) because any prolonged exposure to
catecholamines (both experimentally and clinically) results
in desensitization of the beta-adrenergic pathway. For ex-
ample, 5 days of treatment with a beta-adrenergic agonist in
the rat results in total loss of the myocardial inotropic
responses to pirbuterol and prenalterol, two orally active
beta-adrenergic agonists (8)
.
Because intermittent exposure to cateeholamines may
circumvent the development of tolerance, intermittent ther-
apy' with beta-agonists could conceivably avoid the limita-
tions
of
continuous treatment . When preliminary data (9,10)
suggested that intermittent infusions of dobutamine could
favorably affect the clinical stator of patients with chronic
heart failure, this therapeutic approach was prospectively
evaluated in a controlled trial (11,12)
. Sixty patients with
severe chronic heart failure (ivew York Heart Association
functional classes III and IV) were randomly assigned to
placebo (n = 29) or dobutamine In = 31) . After an initial
in-hospital evaluation of intravenous dobutamine therapy,
patients were discharged home for 24 weeks, where they
received an infusion of dobutamine (mean dose 8 .1 pgikg per
min) or placebo for 48 h each week by way of an ambulatory,
battery-driven infusion pump; 5 days elapsed bt'ween each
infusion of the drag. Exercise capacity increased more in
dobutamine-treated patients than in patients treated with
placebo (dobutamine +91%; placebo +13% ; p < 0.05)
(11,12) . In addition, clinical deterioration occurred less
frequently in the dobutamine-treated group ; seven patients
were crossed over from placebo to dobutamine because of
worsening symptoms of heart failure, whereas only one
